PKG drug G1 NEW
| Price | $51 | $79 | $158 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: PKG drug G1 | CAS No.: 374703-78-3 |
| Purity: 99.41% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | PKG drug G1 |
| Description | PKG drug G1 targets PKG Iα C42. PKG drug G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism. |
| Animal Research | Mice constitutively expressing PKG Iα Cys42Ser are generated on a pure C57BL/6 background. Age-matched and. body weight–matched WT or PKG Iα Cys42Ser KI male mice are used in all studies. Blood pressure and heart rate are. assessed by radio telemetry in conscious freely moving mice. Alzet osmotic mini-pumps are used to deliver. angiotensin II at 1.1 mg/kg per day in some studies. PKG drug G1 is delivered intraperitoneally (3.7-14.8 mg/kg) or. orally (20 mg/kg) in some studies. To deliver PKG drug G1 orally, without stress or risk of dislodging the telemetric. probe catheter, it is provided suspended in water and set in gelatin flavored with sodium saccharin. |
| In vivo | The absorption rate following oral administration is 80% in rats and >90% in dogs and monkeys. The metabolism of Asimadoline is rapid and appears similar in animals and man. Asimadoline has peripheral anti-inflammatory actions that are partly mediated through increase in joint fluid substance P levels |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 16.67 mg/mL (64.77 mM) |
| Keywords | PKG drug G 1 | PKG drug G-1 | PKG drug G1 | Inhibitor | inhibit |
| Inhibitors Related | Daphnetin | Capivasertib | Ellagic acid | GSK180736A | Acefylline | Ro-3306 | Metadoxine | Staurosporine | 8-Bromo-cAMP sodium salt | H-8 hydrochloride | Fasudil hydrochloride | JAK1/2/3 Inhibitor 1 |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Obesity Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $232.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $100.00/10g |
Hebei Aicrowe Biotech Co., Ltd
|
2019-05-14 | ||
| $0.00/10mg |
Guangzhou PI PI BIOTECH INC
|
2022-04-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY